The United States has introduced 100% tariffs on patented medicines entering the country, marking a significant shift in trade policy that could reshape global pharmaceutical supply chains. President Donald Trump announced these tariffs on March 3, positioning the move as essential for national security and domestic manufacturing growth.
Here's what you need to understand about this policy change and its potential impact on global markets, including opportunities for African investors and businesses.
How the Tariff System Works
The new tariffs don't apply universally. Generic medicines – which make up the majority of prescriptions filled in the US – remain exempt from these charges. This means the immediate impact may be more limited than the headline suggests.
Companies have several paths to reduce their tariff burden. Pharmaceutical firms that commit to building new manufacturing facilities in the US before January 2029 will pay only 20% tariffs instead of the full 100%. Those willing to negotiate pricing agreements with the US government can eliminate tariffs entirely.
These pricing deals typically involve selling medicines to government health programs like Medicaid at prices similar to what companies charge in other international markets.
International Agreements Provide Relief
The US has already secured agreements with several key partners, including Europe, Switzerland, the UK, South Korea, and Japan. Under these deals, pharmaceutical companies from these regions face lower or zero tariffs.
The UK-US agreement serves as an interesting case study. British pharmaceutical companies maintain zero tariffs on exports to America for three years, but the UK's National Health Service will pay higher prices for medicines in return.
What This Means for African Opportunities
For African entrepreneurs and investors, this policy creates both challenges and opportunities. While it makes US market entry more expensive for pharmaceutical companies globally, it also signals growing demand for domestic manufacturing partnerships.
African pharmaceutical companies looking to access the US market should consider the long-term benefits of establishing manufacturing partnerships or facilities in America. Sean Sullivan, a professor at the University of Washington and London School of Economics, notes that the policy aims to bring companies "to the bargaining table" – creating leverage for negotiations.
Many major pharmaceutical companies have already struck agreements to avoid the full tariffs, with more expected to follow. This suggests the policy functions more as a negotiating tool than a permanent trade barrier.
For investors tracking pharmaceutical stocks or considering healthcare investments, monitor how companies in your portfolio respond to these tariffs through manufacturing commitments or pricing negotiations.